Motley Quoting Adam F " GSK IS A POSITIVE FOR SRPT" also The Street Aticle.
Why Sarepta Therapeutics Shares Shot Higher
GlaxoSmithKline (NYSE: GSK ) disclosed safety data from its early stage trial of drisapersen, which showed that some patients had to be hospitalized because of kidney toxicity and low platelet counts. The news stands to benefit Sarepta, whose lead drug candidate is Eteplirsen in DMD and has demonstrated a tame adverse event profile through clinical trials.
Now what: Glaxo didn't offer any additional information about those patients who were hospitalized over the previous two years, but clearly this is another step in the right direction for Sarepta if its competitors are faltering. If you recall, Sarepta's Eteplirsen not only curbed progression of the disease, but actually improved walking distance over a six-minute period in trials -- a truly astonishing result should it hold up in further testing and translate over to the general DMD-suffering population. Sarepta is definitely a name you must have on your watchlist.
By Sean Williams |